Olopatadine

Olopatadine

Systematic (IUPAC) name
{(11Z)-11-[3-(dimethylamino)propylidene]-6,11- dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
Clinical data
Trade names	Patanol
AHFS/Drugs.com	monograph
MedlinePlus	a602025
Pregnancy cat.	C
Legal status	?
Routes	Ophthalmic, intranasal, oral
Pharmacokinetic data
Half-life	3 hours
Identifiers
CAS number	113806-05-6 Y
ATC code	S01GX09 R01AC08
PubChem	CID 5281071
DrugBank	APRD00310
ChemSpider	4444528 Y
UNII	D27V6190PM Y
KEGG	D08293 Y
ChEMBL	CHEMBL1189432 N
Chemical data
Formula	C21H23NO3
Mol. mass	337.412 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- Y Key:JBIMVDZLSHOPLA-LSCVHKIXSA-N Y
N(what is this?)  (verify)

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic) and mast cell stabilizer, sold as a prescription eye drop (0.2% solution, Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as Patanol (or Opatanol in some countries). A nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008. It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion.

Olopatadine was developed by Kyowa Hakko Kogyo.

External links

• Pataday website
• Patanase website
• Olopatadine Ophthalmic via MedlinePlus